Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been recognized as potent antioxidant agents. Since SGLT2i are nephroprotective drugs, we aimed to examine the urine antioxidant status in patients with type 2 diabetes mellitus (T2DM). One hundred and one subjects participated in this study, i...
Gespeichert in:
| Veröffentlicht in: | Oxidative medicine and cellular longevity 2021, Vol.2021 (1), p.5593589-5593589 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5593589 |
|---|---|
| container_issue | 1 |
| container_start_page | 5593589 |
| container_title | Oxidative medicine and cellular longevity |
| container_volume | 2021 |
| creator | Nabrdalik-Leśniak, Diana Nabrdalik, Katarzyna Sedlaczek, Katarzyna Główczyński, Patryk Kwiendacz, Hanna Sawczyn, Tomasz Hajzler, Weronika Drożdż, Karolina Hendel, Mirela Irlik, Krzysztof Stelmach, Paweł Adamczyk, Piotr Paradysz, Andrzej Kasperczyk, Sławomir Stompór, Tomasz Gumprecht, Janusz |
| description | Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been recognized as potent antioxidant agents. Since SGLT2i are nephroprotective drugs, we aimed to examine the urine antioxidant status in patients with type 2 diabetes mellitus (T2DM). One hundred and one subjects participated in this study, including 37 T2DM patients treated with SGLT2i, 31 T2DM patients not using SGLT2i, and 33 healthy individuals serving as a control group. Total antioxidant capacity (TAC), superoxide dismutase (SOD), manganese superoxide dismutase (MnSOD), free thiol groups (R-SH, sulfhydryl groups), and catalase (CAT) activity, as well as glucose concentration, were assessed in the urine of all participants. Urine SOD and MnSOD activity were significantly higher among T2DM patients treated with SGLT2i than T2DM patients without SGLT2i treatment (p=0.009 and p=0.003, respectively) and to the healthy controls (p=0.002 and p=0.001, respectively). TAC was significantly lower in patients with T2DM treated with SGLT2i when compared to those not treated and healthy subjects (p=0.036 and p=0.019, respectively). It could be hypothesized that the mechanism by which SGLT2i provides nephroprotective effects involves improvement of the SOD antioxidant activity. However, lower TAC might impose higher OS (oxidative stress), and elevation of SOD activity might be a compensatory mechanism. |
| doi_str_mv | 10.1155/2021/5593589 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8294983</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2557540588</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-2177508771303cd223b9391ad158e9e528688d8bb777ea3423fe7545140d24553</originalsourceid><addsrcrecordid>eNp9kc1vEzEQxS1UREvh1nNlqRckSOvPrM0BKSpQIkVqpaZny7s7S1zt2sH2AvnvcZQQlR44jTX-zZt5egidUXJJqZRXjDB6JaXmUukX6IRqwSZEa3F0eBNyjF6n9EjIlDNBX6FjLjifUiJO0DD3XT-CbwCHDt_fLJYMz_3K1S6HiJcRbB7AZxw8fojOA5757MJv19rSvM82jwk7j5ebNWCGPztbQ3YNvrPZlbH0Ec_wnevDlh3bzRv0srN9grf7eooevn5ZXn-bLG5v5tezxaSRVOQJo1UliaoqyglvWsZ4rbmmtqVSgQbJ1FSpVtV1VVVguWC8g0qKMktaJqTkp-jTTnc91gO0TTkl2t6soxts3Jhgnfn3x7uV-R5-GsW00IoXgXd7gRh-jJCyGVxqoO-thzAmw6QsC4lUqqAXz9DHMEZf7G0poYoNRgr1YUc1MaQUoTscQ4nZ5mi2OZp9jgU_f2rgAP8NrgDvd8DK-db-cv-X-wPOfqLz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2554887720</pqid></control><display><type>article</type><title>Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Nabrdalik-Leśniak, Diana ; Nabrdalik, Katarzyna ; Sedlaczek, Katarzyna ; Główczyński, Patryk ; Kwiendacz, Hanna ; Sawczyn, Tomasz ; Hajzler, Weronika ; Drożdż, Karolina ; Hendel, Mirela ; Irlik, Krzysztof ; Stelmach, Paweł ; Adamczyk, Piotr ; Paradysz, Andrzej ; Kasperczyk, Sławomir ; Stompór, Tomasz ; Gumprecht, Janusz</creator><contributor>Peluso, Ilaria ; Ilaria Peluso</contributor><creatorcontrib>Nabrdalik-Leśniak, Diana ; Nabrdalik, Katarzyna ; Sedlaczek, Katarzyna ; Główczyński, Patryk ; Kwiendacz, Hanna ; Sawczyn, Tomasz ; Hajzler, Weronika ; Drożdż, Karolina ; Hendel, Mirela ; Irlik, Krzysztof ; Stelmach, Paweł ; Adamczyk, Piotr ; Paradysz, Andrzej ; Kasperczyk, Sławomir ; Stompór, Tomasz ; Gumprecht, Janusz ; Peluso, Ilaria ; Ilaria Peluso</creatorcontrib><description>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been recognized as potent antioxidant agents. Since SGLT2i are nephroprotective drugs, we aimed to examine the urine antioxidant status in patients with type 2 diabetes mellitus (T2DM). One hundred and one subjects participated in this study, including 37 T2DM patients treated with SGLT2i, 31 T2DM patients not using SGLT2i, and 33 healthy individuals serving as a control group. Total antioxidant capacity (TAC), superoxide dismutase (SOD), manganese superoxide dismutase (MnSOD), free thiol groups (R-SH, sulfhydryl groups), and catalase (CAT) activity, as well as glucose concentration, were assessed in the urine of all participants. Urine SOD and MnSOD activity were significantly higher among T2DM patients treated with SGLT2i than T2DM patients without SGLT2i treatment (p=0.009 and p=0.003, respectively) and to the healthy controls (p=0.002 and p=0.001, respectively). TAC was significantly lower in patients with T2DM treated with SGLT2i when compared to those not treated and healthy subjects (p=0.036 and p=0.019, respectively). It could be hypothesized that the mechanism by which SGLT2i provides nephroprotective effects involves improvement of the SOD antioxidant activity. However, lower TAC might impose higher OS (oxidative stress), and elevation of SOD activity might be a compensatory mechanism.</description><identifier>ISSN: 1942-0900</identifier><identifier>EISSN: 1942-0994</identifier><identifier>DOI: 10.1155/2021/5593589</identifier><identifier>PMID: 34336104</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Acids ; Antioxidants ; Antioxidants - metabolism ; Creatinine ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - urine ; Enzymes ; Glucose ; Humans ; Hydrogen peroxide ; Middle Aged ; Oxidation ; Pilot Projects ; Sodium-Glucose Transporter 2 Inhibitors - pharmacology ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use ; Urine</subject><ispartof>Oxidative medicine and cellular longevity, 2021, Vol.2021 (1), p.5593589-5593589</ispartof><rights>Copyright © 2021 Diana Nabrdalik-Leśniak et al.</rights><rights>Copyright © 2021 Diana Nabrdalik-Leśniak et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Diana Nabrdalik-Leśniak et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-2177508771303cd223b9391ad158e9e528688d8bb777ea3423fe7545140d24553</citedby><cites>FETCH-LOGICAL-c514t-2177508771303cd223b9391ad158e9e528688d8bb777ea3423fe7545140d24553</cites><orcidid>0000-0001-9557-221X ; 0000-0003-1584-1796 ; 0000-0001-7091-2118 ; 0000-0002-9481-8174 ; 0000-0001-8974-5786 ; 0000-0003-2260-6380 ; 0000-0002-1256-0414 ; 0000-0001-8088-7681 ; 0000-0002-0777-8048 ; 0000-0003-1742-8372 ; 0000-0001-9699-1686 ; 0000-0002-5423-4553 ; 0000-0002-0140-0917 ; 0000-0002-3944-0850 ; 0000-0002-0341-3762 ; 0000-0003-4267-740X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294983/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294983/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4009,27902,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34336104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Peluso, Ilaria</contributor><contributor>Ilaria Peluso</contributor><creatorcontrib>Nabrdalik-Leśniak, Diana</creatorcontrib><creatorcontrib>Nabrdalik, Katarzyna</creatorcontrib><creatorcontrib>Sedlaczek, Katarzyna</creatorcontrib><creatorcontrib>Główczyński, Patryk</creatorcontrib><creatorcontrib>Kwiendacz, Hanna</creatorcontrib><creatorcontrib>Sawczyn, Tomasz</creatorcontrib><creatorcontrib>Hajzler, Weronika</creatorcontrib><creatorcontrib>Drożdż, Karolina</creatorcontrib><creatorcontrib>Hendel, Mirela</creatorcontrib><creatorcontrib>Irlik, Krzysztof</creatorcontrib><creatorcontrib>Stelmach, Paweł</creatorcontrib><creatorcontrib>Adamczyk, Piotr</creatorcontrib><creatorcontrib>Paradysz, Andrzej</creatorcontrib><creatorcontrib>Kasperczyk, Sławomir</creatorcontrib><creatorcontrib>Stompór, Tomasz</creatorcontrib><creatorcontrib>Gumprecht, Janusz</creatorcontrib><title>Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study</title><title>Oxidative medicine and cellular longevity</title><addtitle>Oxid Med Cell Longev</addtitle><description>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been recognized as potent antioxidant agents. Since SGLT2i are nephroprotective drugs, we aimed to examine the urine antioxidant status in patients with type 2 diabetes mellitus (T2DM). One hundred and one subjects participated in this study, including 37 T2DM patients treated with SGLT2i, 31 T2DM patients not using SGLT2i, and 33 healthy individuals serving as a control group. Total antioxidant capacity (TAC), superoxide dismutase (SOD), manganese superoxide dismutase (MnSOD), free thiol groups (R-SH, sulfhydryl groups), and catalase (CAT) activity, as well as glucose concentration, were assessed in the urine of all participants. Urine SOD and MnSOD activity were significantly higher among T2DM patients treated with SGLT2i than T2DM patients without SGLT2i treatment (p=0.009 and p=0.003, respectively) and to the healthy controls (p=0.002 and p=0.001, respectively). TAC was significantly lower in patients with T2DM treated with SGLT2i when compared to those not treated and healthy subjects (p=0.036 and p=0.019, respectively). It could be hypothesized that the mechanism by which SGLT2i provides nephroprotective effects involves improvement of the SOD antioxidant activity. However, lower TAC might impose higher OS (oxidative stress), and elevation of SOD activity might be a compensatory mechanism.</description><subject>Acids</subject><subject>Antioxidants</subject><subject>Antioxidants - metabolism</subject><subject>Creatinine</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - urine</subject><subject>Enzymes</subject><subject>Glucose</subject><subject>Humans</subject><subject>Hydrogen peroxide</subject><subject>Middle Aged</subject><subject>Oxidation</subject><subject>Pilot Projects</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - pharmacology</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</subject><subject>Urine</subject><issn>1942-0900</issn><issn>1942-0994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kc1vEzEQxS1UREvh1nNlqRckSOvPrM0BKSpQIkVqpaZny7s7S1zt2sH2AvnvcZQQlR44jTX-zZt5egidUXJJqZRXjDB6JaXmUukX6IRqwSZEa3F0eBNyjF6n9EjIlDNBX6FjLjifUiJO0DD3XT-CbwCHDt_fLJYMz_3K1S6HiJcRbB7AZxw8fojOA5757MJv19rSvM82jwk7j5ebNWCGPztbQ3YNvrPZlbH0Ec_wnevDlh3bzRv0srN9grf7eooevn5ZXn-bLG5v5tezxaSRVOQJo1UliaoqyglvWsZ4rbmmtqVSgQbJ1FSpVtV1VVVguWC8g0qKMktaJqTkp-jTTnc91gO0TTkl2t6soxts3Jhgnfn3x7uV-R5-GsW00IoXgXd7gRh-jJCyGVxqoO-thzAmw6QsC4lUqqAXz9DHMEZf7G0poYoNRgr1YUc1MaQUoTscQ4nZ5mi2OZp9jgU_f2rgAP8NrgDvd8DK-db-cv-X-wPOfqLz</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Nabrdalik-Leśniak, Diana</creator><creator>Nabrdalik, Katarzyna</creator><creator>Sedlaczek, Katarzyna</creator><creator>Główczyński, Patryk</creator><creator>Kwiendacz, Hanna</creator><creator>Sawczyn, Tomasz</creator><creator>Hajzler, Weronika</creator><creator>Drożdż, Karolina</creator><creator>Hendel, Mirela</creator><creator>Irlik, Krzysztof</creator><creator>Stelmach, Paweł</creator><creator>Adamczyk, Piotr</creator><creator>Paradysz, Andrzej</creator><creator>Kasperczyk, Sławomir</creator><creator>Stompór, Tomasz</creator><creator>Gumprecht, Janusz</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9557-221X</orcidid><orcidid>https://orcid.org/0000-0003-1584-1796</orcidid><orcidid>https://orcid.org/0000-0001-7091-2118</orcidid><orcidid>https://orcid.org/0000-0002-9481-8174</orcidid><orcidid>https://orcid.org/0000-0001-8974-5786</orcidid><orcidid>https://orcid.org/0000-0003-2260-6380</orcidid><orcidid>https://orcid.org/0000-0002-1256-0414</orcidid><orcidid>https://orcid.org/0000-0001-8088-7681</orcidid><orcidid>https://orcid.org/0000-0002-0777-8048</orcidid><orcidid>https://orcid.org/0000-0003-1742-8372</orcidid><orcidid>https://orcid.org/0000-0001-9699-1686</orcidid><orcidid>https://orcid.org/0000-0002-5423-4553</orcidid><orcidid>https://orcid.org/0000-0002-0140-0917</orcidid><orcidid>https://orcid.org/0000-0002-3944-0850</orcidid><orcidid>https://orcid.org/0000-0002-0341-3762</orcidid><orcidid>https://orcid.org/0000-0003-4267-740X</orcidid></search><sort><creationdate>2021</creationdate><title>Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study</title><author>Nabrdalik-Leśniak, Diana ; Nabrdalik, Katarzyna ; Sedlaczek, Katarzyna ; Główczyński, Patryk ; Kwiendacz, Hanna ; Sawczyn, Tomasz ; Hajzler, Weronika ; Drożdż, Karolina ; Hendel, Mirela ; Irlik, Krzysztof ; Stelmach, Paweł ; Adamczyk, Piotr ; Paradysz, Andrzej ; Kasperczyk, Sławomir ; Stompór, Tomasz ; Gumprecht, Janusz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-2177508771303cd223b9391ad158e9e528688d8bb777ea3423fe7545140d24553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acids</topic><topic>Antioxidants</topic><topic>Antioxidants - metabolism</topic><topic>Creatinine</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - urine</topic><topic>Enzymes</topic><topic>Glucose</topic><topic>Humans</topic><topic>Hydrogen peroxide</topic><topic>Middle Aged</topic><topic>Oxidation</topic><topic>Pilot Projects</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - pharmacology</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nabrdalik-Leśniak, Diana</creatorcontrib><creatorcontrib>Nabrdalik, Katarzyna</creatorcontrib><creatorcontrib>Sedlaczek, Katarzyna</creatorcontrib><creatorcontrib>Główczyński, Patryk</creatorcontrib><creatorcontrib>Kwiendacz, Hanna</creatorcontrib><creatorcontrib>Sawczyn, Tomasz</creatorcontrib><creatorcontrib>Hajzler, Weronika</creatorcontrib><creatorcontrib>Drożdż, Karolina</creatorcontrib><creatorcontrib>Hendel, Mirela</creatorcontrib><creatorcontrib>Irlik, Krzysztof</creatorcontrib><creatorcontrib>Stelmach, Paweł</creatorcontrib><creatorcontrib>Adamczyk, Piotr</creatorcontrib><creatorcontrib>Paradysz, Andrzej</creatorcontrib><creatorcontrib>Kasperczyk, Sławomir</creatorcontrib><creatorcontrib>Stompór, Tomasz</creatorcontrib><creatorcontrib>Gumprecht, Janusz</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oxidative medicine and cellular longevity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nabrdalik-Leśniak, Diana</au><au>Nabrdalik, Katarzyna</au><au>Sedlaczek, Katarzyna</au><au>Główczyński, Patryk</au><au>Kwiendacz, Hanna</au><au>Sawczyn, Tomasz</au><au>Hajzler, Weronika</au><au>Drożdż, Karolina</au><au>Hendel, Mirela</au><au>Irlik, Krzysztof</au><au>Stelmach, Paweł</au><au>Adamczyk, Piotr</au><au>Paradysz, Andrzej</au><au>Kasperczyk, Sławomir</au><au>Stompór, Tomasz</au><au>Gumprecht, Janusz</au><au>Peluso, Ilaria</au><au>Ilaria Peluso</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study</atitle><jtitle>Oxidative medicine and cellular longevity</jtitle><addtitle>Oxid Med Cell Longev</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><issue>1</issue><spage>5593589</spage><epage>5593589</epage><pages>5593589-5593589</pages><issn>1942-0900</issn><eissn>1942-0994</eissn><abstract>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been recognized as potent antioxidant agents. Since SGLT2i are nephroprotective drugs, we aimed to examine the urine antioxidant status in patients with type 2 diabetes mellitus (T2DM). One hundred and one subjects participated in this study, including 37 T2DM patients treated with SGLT2i, 31 T2DM patients not using SGLT2i, and 33 healthy individuals serving as a control group. Total antioxidant capacity (TAC), superoxide dismutase (SOD), manganese superoxide dismutase (MnSOD), free thiol groups (R-SH, sulfhydryl groups), and catalase (CAT) activity, as well as glucose concentration, were assessed in the urine of all participants. Urine SOD and MnSOD activity were significantly higher among T2DM patients treated with SGLT2i than T2DM patients without SGLT2i treatment (p=0.009 and p=0.003, respectively) and to the healthy controls (p=0.002 and p=0.001, respectively). TAC was significantly lower in patients with T2DM treated with SGLT2i when compared to those not treated and healthy subjects (p=0.036 and p=0.019, respectively). It could be hypothesized that the mechanism by which SGLT2i provides nephroprotective effects involves improvement of the SOD antioxidant activity. However, lower TAC might impose higher OS (oxidative stress), and elevation of SOD activity might be a compensatory mechanism.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>34336104</pmid><doi>10.1155/2021/5593589</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9557-221X</orcidid><orcidid>https://orcid.org/0000-0003-1584-1796</orcidid><orcidid>https://orcid.org/0000-0001-7091-2118</orcidid><orcidid>https://orcid.org/0000-0002-9481-8174</orcidid><orcidid>https://orcid.org/0000-0001-8974-5786</orcidid><orcidid>https://orcid.org/0000-0003-2260-6380</orcidid><orcidid>https://orcid.org/0000-0002-1256-0414</orcidid><orcidid>https://orcid.org/0000-0001-8088-7681</orcidid><orcidid>https://orcid.org/0000-0002-0777-8048</orcidid><orcidid>https://orcid.org/0000-0003-1742-8372</orcidid><orcidid>https://orcid.org/0000-0001-9699-1686</orcidid><orcidid>https://orcid.org/0000-0002-5423-4553</orcidid><orcidid>https://orcid.org/0000-0002-0140-0917</orcidid><orcidid>https://orcid.org/0000-0002-3944-0850</orcidid><orcidid>https://orcid.org/0000-0002-0341-3762</orcidid><orcidid>https://orcid.org/0000-0003-4267-740X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1942-0900 |
| ispartof | Oxidative medicine and cellular longevity, 2021, Vol.2021 (1), p.5593589-5593589 |
| issn | 1942-0900 1942-0994 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8294983 |
| source | MEDLINE; Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Acids Antioxidants Antioxidants - metabolism Creatinine Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - urine Enzymes Glucose Humans Hydrogen peroxide Middle Aged Oxidation Pilot Projects Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Urine |
| title | Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T06%3A24%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20SGLT2%20Inhibitor%20Treatment%20on%20Urine%20Antioxidant%20Status%20in%20Type%202%20Diabetic%20Patients:%20A%20Pilot%20Study&rft.jtitle=Oxidative%20medicine%20and%20cellular%20longevity&rft.au=Nabrdalik-Le%C5%9Bniak,%20Diana&rft.date=2021&rft.volume=2021&rft.issue=1&rft.spage=5593589&rft.epage=5593589&rft.pages=5593589-5593589&rft.issn=1942-0900&rft.eissn=1942-0994&rft_id=info:doi/10.1155/2021/5593589&rft_dat=%3Cproquest_pubme%3E2557540588%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2554887720&rft_id=info:pmid/34336104&rfr_iscdi=true |